"Wegovy was driving a strong start to 2026, reflecting growing demand for more convenient weight-loss treatments. The rapid adoption of the pill is significant for the obesity treatment landscape."
"As the global momentum behind peptide-based therapies accelerates, Wegovy pill is defining a novel category as the only oral peptide for the treatment of obesity, setting a new benchmark for patient and physician expectations."
Novo Nordisk has increased its annual outlook due to high demand for its Wegovy weight-loss pill, which surpassed market expectations. The pill, launched in January, achieved the strongest debut for an obesity treatment in the U.S., with over two million prescriptions issued. Sales reached 2.26 billion Danish krone in the first quarter, exceeding forecasts. The company is competing with Eli Lilly in the weight-loss market, and Wegovy is establishing a new category of oral GLP-1 therapies, complementing existing injectable options.
Read at London Business News | Londonlovesbusiness.com
Unable to calculate read time
Collection
[
|
...
]